



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gary D. Glick *et al.*
Serial No.: 09/767,283
Filed: 01/22/2001
Entitled:

Group No.: 1618
Examiner: Kim, Vickie Y.

**Use of Benzodiazepines for Treating Autoimmune
Disease Induced by Apoptosis**

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: January 23, 2006

By: 


Mary E. Waite

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office.

Applicants believe that no fee is required. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee, and/or credit any overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: January 23, 2006




Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Application of: Gary D. Glick *et al.*
Serial No.: 09/767,283
Filed: 01/22/2001
Entitled: **Therapeutic Applications Of Pro-Apoptotic
Benzodiazepines**

Group No.:
Examiner:



SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.


- US Patent 6,506,744, Issued 01/14/2003, Alig, et al
- US Patent 6,767,533, Issued 07/27/2004, Casellas, et al
- Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770
- Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861
- Hulme, C. J. Org. Chem., 63,(1998), 8021-8023
- Kamal, A. Synlett, 14,(2004), 2533-35
- Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912
- Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484

- Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: _____

1-23-2006
January 23, 2006



Robert A. Goetz

Registration No. 55,210

MEDLEN & CARROLL, LLP

101 Howard Street, Suite 350

San Francisco, California 94105

608/218-6900

Complete if Known

Application Number	09/767,283
Filing Date	01/22/2001
First Named Inventor	GLICK, et al
Art Unit	1618
Examiner Name	Kim, Vickie Y
Attorney Docket Number	UM-07269

Sheet	1	of	2
-------	---	----	---

[illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/767,283
Filing Date	01/22/2001
First Named Inventor	Glick
Art Unit	1618
Examiner Name	Kim, Vickie Y.
Attorney Docket Number	UM-07269



Sheet 2 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	3	Parks, Daniel J. Bioorg Med Chem. Ltrs., 15,(2005), 765-770	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023	
	6	Kamal, A. Synlett, 14,(2004), 2533-35	
	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912	
	8	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484	
	9	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.